Eisai has added to its genomics capabilities. The latest move sees the Japanese drugmaker's nascent Integrated Human Genomics (IHGx) Research Unit team up with Genomics plc, an Oxford University spinout founded in response to the United Kingdom's 100,000 Genomes Project.
Schrödinger has racked up another tech-validating deal. Having seen the biotech it helped to found rake in $43 million from Pfizer and others last month, the computational drug design veteran has now struck a $120 million discovery deal with Sanofi.
The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.
Researchers at the University of Michigan are trying to speed toward their goal of enrolling 20,000 people in a study by piggybacking onto Facebook's vast social network. And the genotypic and phenotypic data gathering project is off to a brisk start, with more than 2,000 people signing up in the days after its public launch.
Medidata has bolstered its books with two new deals. Accenture is tightening the ties between its R&D service offering and Medidata's Clinical Cloud and Rave EDC system.
Celgene and Genentech are funding a clinical trial innovation prize focused on doubling the rate of participation in studies of cancer drugs. The project is challenging the crowd to submit ideas and evidence of their effectiveness in return for the chance to land a piece of the $75,000 prize kitty.
Genome Canada is aiming to retool the country's genomics infrastructure by plowing $12.2 million in federal funding and a similar amount from other sources into 10 research centers.
Cincinnati Children's Hospital Medical Center has received $2.2 million from the National Institutes of Health (NIH) to track children who have rare genetic disorders.
Analysts at MarketsandMarkets have looked into their crystal ball and come up with a forecast of the pharmacovigilance and drug safety software sector. The authors predict the value of the market will top $150 million by 2019, with Asia and Latin America tipped to be the driving forces behind growth over the next few years.
Harvard geneticist George Church has backed Open Humans, an online platform that asks people to openly share their genomes and other personal data. The idea is to marry the underlying principles of the open-source and quantified-self movements to make more data available to more researchers.
An independent committee set up to probe a dispute over Europe's $1 billion Human Brain Project (HBP) has sided with critics of the initiative. The outcome leaves the fate of HBP and its ambitious and much-criticized plan to simulate the brain using a supercomputer in doubt.
The United Kingdom has wasted no time getting industry involved with its 100,000 Genomes Project. With just 3% of the sequencing work done, Genomics England has enlisted the help of a who's who of Big Pharma companies to pore over the data in search of new avenues for drug discovery.
Amgen's deCODE Genetics has released a glimpse of a future in which population-scale genome sequencing forms the basis of drug discovery programs. And while the initiative still has some technical shortcomings and has yet to prove to the outside world it is worth $415 million, it nonetheless sparked excitement in the genomics community.
India has given consumers a way to complain about the availability or pricing of drugs. By providing an online portal and mobile app through which consumers can vent their grievances, Indian authorities are trying to turn the country's vast population into a disaggregated army of whistleblowers.
The Financial Times has taken a look at the implications of Apple and Google's ever-growing interest in healthcare and life sciences.
Having faced years of criticism for its failure to publish guidelines on how the industry can use social media, the FDA is now being chastised by the advocacy group Union of Concerned Scientists over its lack of a policy for its staff.
Cloud Pharmaceuticals has taken the next step in its push to create a pipeline of drugs discovered using a computer-based design process, hooking up with the University of Florida to transition its computer-discovered drugs into traditional preclinical research.
The list of IT vendors and service providers that have yet to strike a deal with AstraZeneca in 2015 keeps getting shorter. Assay Depot is the latest name to cross of the list after the scientific services marketplace agreed to create a private research e-commerce platform for AstraZeneca.
Nimbus Therapeutics is ready to see how the compounds it discovered with the help of Schrödinger's computational chemistry tools fare in the clinic. And the VC units of Eli Lilly, GlaxoSmithKline and Pfizer want to find out, too, prompting each to chip in to Nimbus' $43 million Series B round.
UCB is hosting a hackathon focused on developing new tools to improve the day-to-day lives of people with epilepsy and their families, PMLiVE reports.